Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders
Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug…
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders
Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say this antibody complements its blockbuster product Vyvgart, offering a different mechanism of action but similar pipeline-in-a-product potential. The post Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook…
Donor Government Funding for HIV in Low- and Middle-Income Countries in 2025
This report provides an analysis of donor government funding to address the HIV response in low- and middle-income countries in 2025, the latest year available, as well as trends over time. It includes both bilateral funding from donors and their multilateral contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), UNITAID,…
Donor Government Funding for HIV Drops by $2.1 Billion in 2025 Due to Declines in Funding from the United States, Marking Largest Annual Decrease Since Scale-up for the HIV Response Began
Donor government funding to combat HIV in low- and middle-income countries fell by $2.1 billion in 2025, a 25% decrease from the previous year, according to a new report by KFF and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Total disbursements dropped to $6.2 billion in 2025, down from $8.
Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative
When staff are overextended and patients face delays or abandon care, the issue is no longer a narrow administrative burden. It becomes a business, financial, and access challenge that demands a different operating model. The post Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative appeared first on MedCity News.
How AI Inside Clinical Workflows Is Unlocking Patient Throughput
The question is not whether the technology is impressive. The question is whether it shows up at the right time, with the right information, inside the workflow where the decision is being made. Anything else is just another report. The post How AI Inside Clinical Workflows Is Unlocking Patient Throughput appeared first on MedCity News.
AI Readiness Starts with Solving Healthcare’s Data Fragmentation Problem
[Sponsored] On a recent webinar sponsored by Verato, panelists from SCAN Health Group and the Alliance of Community Health Plans discussed how their organizations are meeting the moment. The post AI Readiness Starts with Solving Healthcare’s Data Fragmentation Problem appeared first on MedCity News.
What Happens When Patients Trust AI Over Their Doctor?
As patients increasingly bring AI chatbot advice into exam rooms, where does liability land when that advice goes wrong? Health law attorney Meghan O’Connor said the answer still isn’t clear, but silence is the riskiest response for providers. The post What Happens When Patients Trust AI Over Their Doctor? appeared first on MedCity News.
Trump Administration Demands Hospitals Share Emergency Room Records
A tiny federal agency tasked with protecting the public from injuries caused by lawn mowers and coffeemakers is demanding that some of the nation’s biggest health systems turn over detailed, personally identifiable medical records of all patients who seek help at their emergency rooms. The Consumer Product Safety Commission, responsible for tracking and issuing recalls…
Tracking State Rural Health Transformation Plans
The five-year, $50 billion Rural Health Transformation program was created as part of the One Big Beautiful Bill Act to expand access to healthcare. States competed to win funding with first-year allocations ranging from $147 million for New Jersey to $281 million for Texas. Find links to available public documents for each state below. KFF…
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as molecule that Sobi added to its pipeline through a $950 million acquisition. The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity…
